GYNECOLOGIC CANCER: Edited by Gottfried E. KonecnyPARP inhibitors in the treatment of ovarian cancer: a reviewWashington, Christina R.; Moore, Kathleen N. Author Information Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Oklahoma Health Science Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA Correspondence to Kathleen N. Moore, MD, MS, 800 NE 10th St, Stephenson Cancer Center, Suite 5050, Oklahoma City, OK 73104, USA. Tel: +1 405 271 8707; fax: +1 405 271 1006; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology: February 2021 - Volume 33 - Issue 1 - p 1-6 doi: 10.1097/GCO.0000000000000675 Buy Metrics Abstract Purpose of review This article will review recent changes in the standard of care for olaparib, niraparib, and rucaparib, as well as ongoing trials evaluating this class of drugs in combination with antiangiogenic agents and PD-1/PD-L1 inhibitors. Recent findings Niraparib received FDA approval for use in patients with complete response or partial response to first-line platinum-based chemotherapy regardless of BRCAm or HRD status that was received in April 2020. FDA approval was received for olaparib in combination with bevacizamab for epithelial ovarian cancer patients with complete response/partial response to first-line chemotherapy and bevacizumab and g/sBRCA and/or genomic instability by Myriad myChoice CDx in May 2020. Summary In the last year, treatment with PARPi has extended to not only include BRCAm and HRD-deficient patients but also have shown improvement in outcomes in HRD-proficient patients. With these advancements, more patients can access these agents and receive benefit. In the upcoming years, it will be exciting to see the potential benefit when PARPs are added to other angiogenic antagonists and immunotherapy agents. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.